Enhancing temozolomide in vivo stability and efficacy through hybrid nanoconjugate approach for improved glioblastoma multiforme treatment
Temozolomide (TMZ) is considered as a standard-of-care DNA alkylating agent for treating glioblastoma multiforme. Despite being a highly potent molecule, TMZ poses several limitations, including short half-life, rapid metabolism, low brain bioavailability and dose-dependent toxicities. Attempts have...
Saved in:
Main Authors: | Prabhjeet Singh, Deepak Kumar Sahel, Reena Jatyan, Kiran Bajaj, Anupama Mittal, Deepak Chitkara |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-06-01
|
Series: | Asian Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S181808762500008X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Acoustic Pressure on Temozolomide-Loaded Oleic Acid-Based Liposomes and Its Safety to Brain Tissue
by: Vasilisa D. Dalinina, et al.
Published: (2025-06-01) -
Reactive astrocytes and glioblastoma: are there new targets for more effective antitumor therapy?
by: E. E. Tyagunova, et al.
Published: (2023-09-01) -
SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma
by: Chia-Hung Chien, et al.
Published: (2022-07-01) -
Case Report: Improved hearing in a rare, adult IDH2-mutant brainstem astrocytoma successfully treated with radiation and temozolomide
by: Takuya Okada, et al.
Published: (2025-07-01) -
Hydrogels in Veterinary Vaccine Development: Types, Mechanisms, and Applications
by: Peisen Zhao, et al.
Published: (2025-06-01)